CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Lyra Therapeutics, Inc. - LYRA CFD

    3.86
    0.26%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.07
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Lyra Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 3.86
    Open* 3.85
    1-Year Change* -28.17%
    Day's Range* 3.64 - 4.02
    52 wk Range 1.86-6.48
    Average Volume (10 days) 48.27K
    Average Volume (3 months) 3.39M
    Market Cap 186.79M
    P/E Ratio -100.00K
    Shares Outstanding 49.55M
    Revenue 1.24M
    EPS -1.59
    Dividend (Yield %) N/A
    Beta -0.14
    Next Earnings Date Nov 6, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 29, 2023 3.87 0.08 2.11% 3.79 4.02 3.62
    Sep 28, 2023 3.86 0.16 4.32% 3.70 4.01 3.66
    Sep 27, 2023 3.68 -0.10 -2.65% 3.78 3.95 3.63
    Sep 26, 2023 3.76 0.08 2.17% 3.68 3.88 3.49
    Sep 25, 2023 3.70 0.12 3.35% 3.58 3.80 3.48
    Sep 22, 2023 3.64 -0.55 -13.13% 4.19 4.28 3.46
    Sep 21, 2023 4.34 0.06 1.40% 4.28 4.44 4.17
    Sep 20, 2023 4.37 -0.32 -6.82% 4.69 4.76 4.17
    Sep 19, 2023 4.79 0.23 5.04% 4.56 4.81 4.55
    Sep 18, 2023 4.55 0.38 9.11% 4.17 4.68 4.13
    Sep 15, 2023 4.33 -0.31 -6.68% 4.64 4.77 4.30
    Sep 14, 2023 4.72 0.13 2.83% 4.59 5.01 4.59
    Sep 13, 2023 4.65 0.21 4.73% 4.44 4.95 4.42
    Sep 12, 2023 4.55 -0.18 -3.81% 4.73 4.89 4.30
    Sep 11, 2023 4.22 0.38 9.90% 3.84 4.26 3.78
    Sep 8, 2023 3.78 0.12 3.28% 3.66 3.91 3.58
    Sep 7, 2023 3.74 0.24 6.86% 3.50 3.83 3.37
    Sep 6, 2023 3.55 0.07 2.01% 3.48 3.60 3.37
    Sep 5, 2023 3.46 0.14 4.22% 3.32 3.59 3.32
    Sep 1, 2023 3.47 0.14 4.20% 3.33 3.62 3.33

    Lyra Therapeutics, Inc. Events

    Time (UTC) Country Event
    Monday, November 6, 2023

    Time (UTC)

    10:59

    Country

    US

    Event

    Q3 2023 Lyra Therapeutics Inc Earnings Release
    Q3 2023 Lyra Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 1.363 0.285 0 0 1.244
    Revenue 1.363 0.285 0 1.244
    Total Operating Expense 57.669 43.9 22.209 16.519 8.503
    Selling/General/Admin. Expenses, Total 17.556 14.206 9.687 4.487 3.528
    Research & Development 38.797 29.694 12.522 12.032 4.975
    Operating Income -56.306 -43.615 -22.209 -16.519 -7.259
    Interest Income (Expense), Net Non-Operating 1.041 0.102 0.082 0.213 0.036
    Other, Net 0 1.194
    Net Income Before Taxes -55.265 -43.513 -22.127 -16.306 -6.029
    Net Income After Taxes -55.278 -43.513 -22.127 -16.306 -6.029
    Net Income Before Extra. Items -55.278 -43.513 -22.127 -16.306 -6.029
    Net Income -55.278 -43.513 -22.127 -16.306 -6.029
    Income Available to Common Excl. Extra. Items -55.278 -43.513 -22.242 -16.306 -6.029
    Income Available to Common Incl. Extra. Items -55.278 -43.513 -22.242 -16.306 -6.029
    Diluted Net Income -55.278 -43.513 -22.242 -16.306 -6.029
    Diluted Weighted Average Shares 30.2357 12.9861 8.59021 12.3996 12.3996
    Diluted EPS Excluding Extraordinary Items -1.82824 -3.35074 -2.58923 -1.31505 -0.48623
    Dividends per Share - Common Stock Primary Issue 0 0
    Diluted Normalized EPS -1.79995 -3.35074 -2.58923 -1.31505 -0.48623
    Total Adjustments to Net Income -0.115
    Unusual Expense (Income) 1.316
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0.458 0.41 0.011 0.359 0.993
    Total Operating Expense 16.961 17.723 15.166 15.185 27.318
    Selling/General/Admin. Expenses, Total 4.57 5.127 4.399 5.137 8.02
    Research & Development 10.799 12.596 9.451 10.048 19.298
    Operating Income -16.503 -17.313 -15.155 -14.826 -26.325
    Interest Income (Expense), Net Non-Operating 0.897 1.072 0.933 0.06 0.048
    Net Income Before Taxes -15.606 -16.241 -14.222 -14.766 -26.277
    Net Income After Taxes -15.618 -16.255 -14.235 -14.766 -26.277
    Net Income Before Extra. Items -15.618 -16.255 -14.235 -14.766 -26.277
    Net Income -15.618 -16.255 -14.235 -14.766 -26.277
    Total Adjustments to Net Income
    Income Available to Common Excl. Extra. Items -15.618 -16.255 -14.235 -14.766 -26.277
    Income Available to Common Incl. Extra. Items -15.618 -16.255 -14.235 -14.766 -26.277
    Diluted Net Income -15.618 -16.255 -14.235 -14.766 -26.277
    Diluted Weighted Average Shares 43.6764 36.8327 36.8994 36.8264 32.4204
    Diluted EPS Excluding Extraordinary Items -0.35758 -0.44132 -0.38578 -0.40096 -0.81051
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.33389 -0.44132 -0.3626 -0.40096 -0.81051
    Revenue 0.458 0.41 0.011 0.359 0.993
    Unusual Expense (Income) 1.592 1.316
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 100.829 47.918 75.917 10.119 24.927
    Cash and Short Term Investments 97.894 45.747 74.593 9.808 23.888
    Cash & Equivalents 32.55 45.747 74.593 9.808 23.888
    Total Receivables, Net 0 0.167
    Prepaid Expenses 2.935 2.171 1.324 0.311 0.872
    Total Assets 109.968 54.867 80.83 14.963 25.359
    Property/Plant/Equipment, Total - Net 4.466 5.858 4.466 3.419 0.103
    Property/Plant/Equipment, Total - Gross 8.64 9.737 7.344 6.248 2.905
    Accumulated Depreciation, Total -4.174 -3.879 -2.878 -2.829 -2.802
    Other Long Term Assets, Total 4.673 1.091 0.447 1.425 0.329
    Total Current Liabilities 14.47 18.246 4.884 5.208 1.96
    Accounts Payable 2.616 3.125 0.922 1.069 0.631
    Accrued Expenses 10.579 5.332 3.962 4.139 1.329
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 29.214 20.551 6.338 7.635 2.08
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 14.744 2.305 1.454 2.427 0.12
    Total Equity 80.754 34.316 74.492 7.328 23.279
    Redeemable Preferred Stock 0 130.666 130.353
    Common Stock 0.032 0.013 0.013 0.008 0.006
    Additional Paid-In Capital 329.387 227.7 224.363 4.411 4.371
    Retained Earnings (Accumulated Deficit) -248.675 -193.397 -149.884 -127.757 -111.451
    Total Liabilities & Shareholders’ Equity 109.968 54.867 80.83 14.963 25.359
    Total Common Shares Outstanding 31.8277 13.0072 12.9324 12.3996 12.3996
    Other Current Liabilities, Total 1.275 9.789
    Short Term Investments 65.344
    Other Equity, Total 0.01
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 84.799 100.829 112.23 122.381 40.555
    Cash and Short Term Investments 82.707 97.894 109.558 120.669 33.755
    Cash & Equivalents 22.019 32.55 109.558 120.669 33.755
    Prepaid Expenses 2.092 2.935 2.343 1.383 1.8
    Total Assets 93.868 109.968 119.463 130.035 47.345
    Property/Plant/Equipment, Total - Net 3.829 4.466 4.361 4.869 5.384
    Property/Plant/Equipment, Total - Gross 8.64 9.085 9.314 9.543
    Accumulated Depreciation, Total -4.174 -4.724 -4.445 -4.159
    Other Long Term Assets, Total 5.24 4.673 2.872 2.785 1.406
    Total Current Liabilities 14.154 14.47 13.605 10.607 21.965
    Accounts Payable 3.951 2.616 2.9 1.67 2.408
    Accrued Expenses 8.693 10.579 7.975 6.391 5.334
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 27.777 29.214 26.241 23.786 24.088
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 13.623 14.744 12.636 13.179 2.123
    Total Equity 66.091 80.754 93.222 106.249 23.257
    Common Stock 0.032 0.032 0.032 0.032 0.013
    Additional Paid-In Capital 331.001 329.387 327.63 325.891 228.552
    Retained Earnings (Accumulated Deficit) -264.93 -248.675 -234.44 -219.674 -205.308
    Total Liabilities & Shareholders’ Equity 93.868 109.968 119.463 130.035 47.345
    Total Common Shares Outstanding 31.8368 31.8277 31.827 31.8264 13.0099
    Other Current Liabilities, Total 1.51 1.275 2.73 2.546 14.223
    Total Receivables, Net 5
    Other Current Assets, Total 0.329 0.329
    Short Term Investments 60.688 65.344
    Other Equity, Total -0.012 0.01
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -55.278 -43.513 -22.127 -16.306 -6.029
    Cash From Operating Activities -43.385 -25.82 -21.143 -13.754 -6.64
    Cash From Operating Activities 1.067 1.001 0.095 0.027 0.082
    Non-Cash Items 6.271 2.77 1.768 0.411 -0.772
    Changes in Working Capital 4.555 13.922 -0.879 2.114 0.079
    Cash From Investing Activities -65.006 -3.385 -1.775 -0.211 -0.037
    Capital Expenditures -0.164 -3.385 -1.775 -0.211 -0.037
    Cash From Financing Activities 96.257 0.359 87.703 -0.115 29.213
    Financing Cash Flow Items -4.246 -0.245 -2.589 -0.226 -0.299
    Issuance (Retirement) of Stock, Net 100.503 0.604 90.292 0.111 29.012
    Issuance (Retirement) of Debt, Net 0 0.5
    Net Change in Cash -12.134 -28.846 64.785 -14.08 22.536
    Other Investing Cash Flow Items, Total -64.842
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -16.255 -55.278 -41.043 -21.496 -7.012
    Cash From Operating Activities -15.85 -43.385 -31.221 -20.375 -11.905
    Cash From Operating Activities 0.284 1.067 0.845 0.566 0.28
    Non-Cash Items 0.884 6.271 3.69 1.951 0.844
    Changes in Working Capital -0.763 4.555 5.287 -1.396 -6.017
    Cash From Investing Activities 5.315 -65.006 -0.136 -0.107 -0.093
    Capital Expenditures -0.045 -0.164 -0.136 -0.107 -0.093
    Cash From Financing Activities 0.004 96.257 96.257 96.493 0.006
    Financing Cash Flow Items 0 -4.246 -4.246 -4.01 -0.002
    Issuance (Retirement) of Stock, Net 0.004 100.503 100.503 100.503 0.008
    Net Change in Cash -10.531 -12.134 64.9 76.011 -11.992
    Other Investing Cash Flow Items, Total 5.36 -64.842

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Lyra Therapeutics, Inc. Company profile

    About Lyra Therapeutics Inc

    Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on development and commercialization of novel drug and delivery solutions for the treatment of patients with ear, nose, and throat (ENT) diseases. Its technology platform, XTreo, is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, are bioresorbable polymeric matrices administered in a non-invasive, in-office procedure to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). LYR-210 is an anti-inflammatory implantable drug matrix based on its XTreo platform that is designed to elute mometasone furoate (MF) to the inflamed mucosal tissue for up to six months in surgically naive CRS patients. LYR-220 is an investigative therapy for CRS patients with and without nasal polyps.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Lyra Therapeutics Inc revenues increased from $0K to $285K. Net loss applicable to common stockholders increased 96% to $43.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase from $12.3M to $29.2M (expense).

    Industry: Biotechnology & Medical Research (NEC)

    480 Arsenal Way
    WATERTOWN
    MASSACHUSETTS 02472
    US

    Income Statement

    • Annual
    • Quarterly

    News

    How to Trade The Triple Top

    Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

    14:13, 27 September 2023
    USA flag on the background of stock charts. Financial system in USA

    Q4 lookahead: US indices starting to show signs of trouble?

    US indices start to draw attention as traders focus on the outlook for Q4.

    07:20, 27 September 2023

    USD/JPY Climbs Towards Key Highs

    USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

    11:32, 26 September 2023

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    People also watch

    Oil - Crude

    90.04 Price
    -1.230% 1D Chg, %
    Long position overnight fee 0.0661%
    Short position overnight fee -0.0881%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    US100

    14,744.20 Price
    +0.120% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0039%
    Overnight fee time 21:00 (UTC)
    Spread 7.0

    BTC/USD

    27,192.30 Price
    +0.290% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    ETH/USD

    1,681.86 Price
    -0.070% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 5.40

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading